Another LNA-based RNA Inhibitor Enters Clinical Trials
Copenhagen (ots/PRNewswire) - - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients With Solid Tumors and Lymphomas Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly ...
plus